One year on from the historic approval of the first new Alzheimer’s med in decades, the world’s largest event focused on the disease is set to take place in San 22 July 2022
One UK-based company is looking to transform the way metabolic disorders are treated, leveraging many of the same AI-based techniques used to great effect elsew 4 July 2022
In the fifth of a series of Industry Leader pieces from biological reagent supplier and service provider Sino Biological, the company answers a series of questi 13 June 2022
Even as generic competition gathers, the treatment landscape in multiple myeloma will likely be dominated by Bristol Myers Squibb’s Revlimid (lenalidomide) for 7 June 2022
“We need to make sure that cancer care gets back on top of the priority list for societies.Cancer is a disease that every second person will face.and many peopl 31 May 2022
Rare diseases powerhouse Alexion was last year acquired for $39 billion by the Anglo-Swedish pharma major AstraZeneca, becoming part of one of big pharma’s most 22 April 2022
At the national level, drug pricing continues to be a hot button issue for lawmakers, drugmakers and patients in the USA. At the state level, could Prescription 4 March 2022
Bold investments in BlueRock, AskBio and Vividion have shown the ambition of Bayer’s new approach towards R&D, and another sign of intent was the German company 28 February 2022
Ever increasing investments are being made in artificial intelligence, as drugmakers spy an opportunity to drive efficiencies and spur innovation. In this episo 30 December 2021
The Johnson & Johnson unit Janssen has been active in neuroscience since the beginnings of the company, with its first product coming in this space, so each new 1 December 2021
Not many companies in the pharmaceutical sector can say that they have kept growing and targeting growth through the pandemic, while maintaining the same commit 26 November 2021
In October 2016, Gabriel Baertschi left his role as president and general manager of AstraZeneca in Japan to take the top job at Germany’s Grünenthal Group. 27 October 2021
New data from a survey of patients prescribed medical cannabis to treat pain shows that 86% found it to be more effective than other medication that they had pr 29 July 2021
Getting celiac disease (CD) diagnosed can be a long and difficult path for patients, and with no effective treatments available, the outcome is often a burdenso 15 June 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.